Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
Purpose
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Malignant Solid Neoplasm
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- 18 years of age or older - Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy - One of the following: - Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment - Completed chemotherapy with no cardiotoxicity at least two years post treatment - Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity - An understanding of the protocol and its requirements, risks, and discomforts - The ability and willingness to sign an informed consent
Exclusion Criteria
- Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Observational | Patients undergo blood sample collection and have their medical records reviewed on study. |
|
Recruiting Locations
Mayo Clinic in Arizona
Scottsdale, Arizona 85259
Scottsdale, Arizona 85259
Mayo Clinic in Florida
Jacksonville, Florida 32224-9980
Jacksonville, Florida 32224-9980
Moffitt Cancer Center
Tampa, Florida 33612
Tampa, Florida 33612
More Details
- Status
- Recruiting
- Sponsor
- Mayo Clinic
Detailed Description
PRIMARY OBJECTIVE: I. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT. OUTLINE: This is an observational study. Patients undergo blood sample collection and have their medical records reviewed on study.